Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Drug Shows Survival Benefit In NSCLC, Raising Its Prospects

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Expectations for Eli Lilly’s ramucirumab were dampened after it failed in a Phase III trial in breast cancer patients, but enthusiasm for the drug has been reignited now that it demonstrated a survival benefit in one of oncology’s riskiest areas – lung cancer.

Advertisement

Related Content

Payback Time For Lilly? Erbitux Follow-on Succeeds In Squamous Lung Cancer Trial

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005684

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel